Eli Lilly & Co. will file with U.S. regulators for accelerated approval of its experimental Alzheimer’s treatment before July, its top scientist said, another move to follow rival Biogen Inc. into the controversial treatment area.
Lilly aims to ask for accelerated approval of donanemab in the second quarter, Chief Scientific Offer Dan Skovronsky said Thursday in an earnings conference call. The drugmaker had announced a delay to the filing earlier this year.
